188 related articles for article (PubMed ID: 15473503)
1. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30.
Krabbe PF; Peerenboom L; Langenhoff BS; Ruers TJ
Qual Life Res; 2004 Sep; 13(7):1247-53. PubMed ID: 15473503
[TBL] [Abstract][Full Text] [Related]
2. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
3. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
Rowen D; Young T; Brazier J; Gaugris S
Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
[TBL] [Abstract][Full Text] [Related]
4. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
[TBL] [Abstract][Full Text] [Related]
5. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
6. Responsiveness of the EQ-5D in breast cancer patients in their first year after treatment.
Kimman ML; Dirksen CD; Lambin P; Boersma LJ
Health Qual Life Outcomes; 2009 Feb; 7():11. PubMed ID: 19200391
[TBL] [Abstract][Full Text] [Related]
7. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
8. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
9. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
[TBL] [Abstract][Full Text] [Related]
10. Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial.
Wu AW; Jacobson KL; Frick KD; Clark R; Revicki DA; Freedberg KA; Scott-Lennox J; Feinberg J
Qual Life Res; 2002 May; 11(3):273-82. PubMed ID: 12074264
[TBL] [Abstract][Full Text] [Related]
11. Good responsiveness with EuroQol 5-Dimension questionnaire and Short Form (36) Health Survey in 20-69 years old patients with a femoral neck fracture: A 2-year prospective follow-up study in 182 patients.
Honkavaara N; Al-Ani AN; Campenfeldt P; Ekström W; Hedström M
Injury; 2016 Aug; 47(8):1692-7. PubMed ID: 27282691
[TBL] [Abstract][Full Text] [Related]
12. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
13. Quality of life after palliative treatment for oesophageal carcinoma -- a prospective comparison between stent placement and single dose brachytherapy.
Homs MY; Essink-Bot ML; Borsboom GJ; Steyerberg EW; Siersema PD;
Eur J Cancer; 2004 Aug; 40(12):1862-71. PubMed ID: 15288288
[TBL] [Abstract][Full Text] [Related]
14. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
15. Performance of the EQ-5D in patients with irritable bowel syndrome.
Bushnell DM; Martin ML; Ricci JF; Bracco A
Value Health; 2006; 9(2):90-7. PubMed ID: 16626412
[TBL] [Abstract][Full Text] [Related]
16. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.
Lorgelly PK; Doble B; Rowen D; Brazier J;
Qual Life Res; 2017 May; 26(5):1163-1176. PubMed ID: 27830513
[TBL] [Abstract][Full Text] [Related]
17. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors.
Méndez Romero A; Wunderink W; van Os RM; Nowak PJ; Heijmen BJ; Nuyttens JJ; Brandwijk RP; Verhoef C; Ijzermans JN; Levendag PC
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1447-52. PubMed ID: 17996394
[TBL] [Abstract][Full Text] [Related]
18. Responsiveness of the testing morbidities index in colonoscopy.
Swan JS; Hur C; Lee P; Motazedi T; Donelan K
Value Health; 2013; 16(6):1046-53. PubMed ID: 24041354
[TBL] [Abstract][Full Text] [Related]
19. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in different states of breast cancer - comparing different instruments.
Rautalin M; Färkkilä N; Sintonen H; Saarto T; Taari K; Jahkola T; Roine RP
Acta Oncol; 2018 May; 57(5):622-628. PubMed ID: 29140139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
